Treatment of invasive cervical cancer in women living with HIV

Export Indicator

The percentage of women living with HIV with suspected invasive cervical cancer who were treated within the last 12 months
What it measures

Progress towards increasing access to treatment for invasive cervical cancer for women living with HIV

Rationale

The purpose of this indicator is to assess availability and access to treatment services for invasive cervical cancer for women living with HIV over time. In the longer run, it is expected that the number of women living with HIV who received treatment for invasive cervical cancer will plateau and slowly decrease, as screening programmes will expand detection and treatment of precancerous lesions, and coverage of human papillomavirus (HPV) vaccination will increase in line with the World Health Organization (WHO) 90-70-90 elimination targets.

Numerator

Number of women living with HIV with suspected invasive cervical cancer who received treatment

Denominator

Number of women living with HIV who were screened for cervical cancer and had suspected invasive cancer

Calculation

Numerator/denominator

Method of measurement

The number is generated from programmatic data from HIV or cervical cancer programmes, or from a national cancer registry, if HIV status is recorded there

Measurement frequency

Annual

Disaggregation
  • Age (15-19, 20-24, 25-29, 30-49, 50+ years).
  • Invasive cervical cancer treatment episode (1st in lifetime, 2nd, 3rd, 4th, etc.).
  • Treatment type: medical, surgical.
  • Cities and other administrative areas of epidemiologic importance.
Additional information requested

Please provide city-specific and other subnational data for this indicator. Space has been created in the data entry sheet to provide information for the capital city and one or two other key administrative areas of high epidemiological relevance, such as those with the highest HIV burden or cities that have committed to ending AIDS by 2030.

Strengths and weaknesses

Changes in this indicator over time should be interpreted in light of related interventions, such as the generalization of the pre-cancer screening and treatment programme.

Variation may also represent changes in health care workers' ability to identify invasive cancer.

Further information

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209-249.

Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240014107).

Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/144785/9789241548953_eng.pdf).

WHO framework for strengthening and scaling-up services for the management of invasive cervical cancer. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240003231).

Guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240030824).